MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA

Colorectal cancer (CRC) is the second most common cause of death from cancer. MicroRNAs (miRNAs) represent a class of small non-coding RNAs that control gene expression by triggering RNA degradation or interfering with translation. Aberrant miRNA expression is involved in human disease including cancer. Herein, we showed that miR-375 was frequently down-regulated in human colorectal cancer cell lines and tissues when compared to normal human colon tissues. PIK3CA was identified as a potential miR-375 target by bioinformatics. Overexpression of miR-375 in SW480 and HCT15 cells reduced PIK3CA protein expression. Subsequently, using reporter constructs, we showed that the PIK3CA untranslated region (3′-UTR) carries the directly binding site of miR-375. Additionally, miR-375 suppressed CRC cell proliferation and colony formation and led to cell cycle arrest. Furthermore, miR-375 overexpression resulted in inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. SiRNA-mediated silencing of PIK3CA blocked the inhibitory effect of miR-375 on CRC cell growth. Lastly, we found overexpressed miR-375 effectively repressed tumor growth in xenograft animal experiments. Taken together, we propose that overexpression of miR-375 may provide a selective growth inhibition for CRC cells by targeting PI3K/Akt signaling pathway.     

MicroRNA-375-3p inhibitor suppresses angiotensin II-induced cardiomyocyte hypertrophy by promoting lactate dehydrogenase B expression

Cardiac hypertrophy is a myocardial enlargement due to overload pressure, and the primary cause of heart failure. We investigated the function of miR-375-3p in cardiac hypertrophy and its regulating mechanisms. miR-375-3p was upregulated in hearts of the transverse aortic constriction rat model and angiotensin II (Ang II)-induced primary cardiomyocyte hypertrophy model; the opposite was observed for lactate dehydrogenase B (LDHB) protein expression. miR-375-3p knockdown reduced the surface area of primary cardiomyocytes increased by Ang II treatment and decreased the B-natriuretic peptide (BNP) and β-myosin heavy chain (β-MHC) messenger RNA (mRNA) and protein levels. miR-375-3p was also observed to directly target LDHB. LDHB knockdown increased the surface area of Ang II-treated primary cardiomyocytes and increased the BNP and β-MHC mRNA and protein levels. LDHB knockdown attenuated the effects of miR-375-3p on the surface area of primary cardiomyocytes and BNP and β-MHC levels. Therefore, miR-375-3p inhibitor suppresses Ang II-induced cardiomyocyte hypertrophy by promoting LDHB expression.     

Exosomal miR-375 promotes the activity of osteoblasts in prostate cancer

Studies have shown that exosomes influence tumour metastasis, diagnosis, and treatment. It has been found that exosomal miRNAs are closely linked to the metastatic microenvironment. However, the regulatory role of exosomes from prostate cancer (PCa) cells in bone metastasis remains poorly understood. Here, exosomes were isolated and purified by ultracentrifugation, total RNA from cells and total miRNA from exosomes were isolated, and the level of miR-375 was analyzed by RT-PCR. Exosome libraries from LNCaP cells and RWPE-1 cells were sequenced and filtered with an Illumina HiSeq^TM 2500 system. The activity of alkaline phosphatase, the extent of extracellular matrix mineralization, and the expression of osteoblast activity-related marker genes were measured to evaluate osteoblast activity. Morphological observation, particle size analysis, and molecular phenotyping confirmed that the isolated extracts contained exosomes. Differential expression analysis confirmed the high expression of miR-375 in LNCaP cell-derived exosomes. This study suggest that exosomes could enter osteoblasts and increase their miR-375 level. In addition, exosomal miR-375 could significantly promote the activity of osteoblasts.This study lays the foundation for further investigations on the function of exosomal miR-375 in the activation and differentiation of osteoblasts and the mechanism of bone metastasis in PCa.     

MicroRNA-148a: A potential therapeutic target for cancer

MicroRNA-148a (miR-148a) which suppresses tumor growth by directly decreasing DNMT1 expression has been demonstrated as an important role for cancer therapy. The mechanisms for miR-148a in cancer will become potential future researches.     

微RNA-375的抑癌机制

微RNA-375（microRNA-375,miR-375）是最早在胰腺组织中发现的微RNA,参与胰岛的形成和发展,具有调节胰岛素分泌的功能. 新近研究发现,miR-375在多种肿瘤组织（包括呼吸系统、消化系统、泌尿生殖系统、皮肤和妇科肿瘤组织）中和食管鳞状细胞癌、肝癌和胰腺癌患者外周血中明显表达异常. miR 375可通过调控多个靶基因（如：3-磷酸肌醇依赖性蛋白激酶1、14-3-3ζ、Janus激酶2、p53、丝裂原活化蛋白激酶、Wnt、血管内皮生长因子、胰岛素样生长因子 1受体、星形胶质细胞升高基因 1/异黏蛋白、地塞米松诱导的Ras相关蛋白1和特异蛋白1等相关基因）,参与肿瘤的发生和发展过程. 提高细胞内miR 375的水平能够抑制肿瘤细胞（如：头颈鳞癌、胃癌、食管鳞癌、黑色素瘤和乳腺癌等肿瘤细胞）的增殖和迁移. 因此,具有抑癌活性的miR 375是一种有临床价值的新型肿瘤分子标志物和肿瘤靶向治疗的新靶点.     

miR-375 在HBV相关性肝细胞癌肿瘤组织与癌旁组织中的表达

目的:比较HBV相关性肝细胞癌患者的肝癌组织与癌旁组织中miR-375的表达。方法:以西京医院进行肝癌切除术治疗的HBs Ag阳性的25例患者为研究对象,收集肝癌组织、癌旁组织及术前外周血标本,并采集相关临床信息。采用反转录和实时荧光定量PCR的方法检测组织中miR-375的表达水平。结果:本研究共收集的25例肝癌患者HBs Ag均为阳性,在肝癌组织中miR-375的表达水平为2.51×10-3±3.61×10-3,显著低于在癌旁组织中的表达水平(15.23×10-3±20.85×10-3;t=3.12,P0.05)。结论:miR-375在HBV相关性肝细胞癌肝癌组织中表达显著下调。     

miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells

MicroRNAs (miRNAs) offer a new approach for molecular classification and individual therapy of human cancer due to their regulation of oncogenic pathways. In a previous report, elevated miR-375 was found in recurring gastric cancer, and it was predicted that miR-375 may be a regulator of p53 gene. However, its biological role and mechanism of actions remain unknown. In this study, we characterized the expression level of miR-375 in gastric cancer cell lines – BGC823, MGC803, SGC7901, AGS, N87, MKN45 – using RT-PCR. We found that exogenous expression of miR-375 promoted the growth of AGS cells in both liquid and soft agar media. In agreement with the previous report, overexpression of miR-375 in AGS cells reduced the p53 protein expression level. A luciferase assay demonstrated that miR-375 down-regulated p53 expression through an interaction with the 3′ UTR region of p53. In addition, the expression of miR-375 desensitizes cells to ionizing radiation and etoposide. Flow cytometry analyses showed that miR-375 abrogated the cell cycle arrest and apoptosis after DNA damage. These results demonstrate that miR-375 targets p53 to regulate the response to ionizing radiation and etoposide treatment.     

miR-375靶向MMP13抑制骨肉瘤细胞的迁移和侵袭

目的 为了探究miR-375是否通过影响基质金属蛋白酶13（MMP13）的表达来调控骨肉瘤（osteosarcoma,OS）恶性特征。方法 用Lipofectamine 3000试剂盒将质粒、miRNA转染至骨肉瘤细胞和HEK293细胞中。实时定量聚合酶链反应（real-time quantitative PCR,RT-qPCR）检测OS患者和OS细胞中miR-375和MMP13的表达。蛋白质印迹法（Western blot）分析OS患者和OS细胞中MMP13蛋白的表达。双荧光素酶法分析miR-375与MMP13的靶向关系。伤口愈合和transwell实验分别分析OS细胞的迁移和侵袭。结果 OS组织中miR-375的表达低于正常组织。MMP13在OS组织中表达上调。在OS患者中,MMP13的表达与miR-375呈负相关。与转染miRNA对照的OS细胞相比,转染miR-375模拟物OS细胞的迁移和侵袭明显被抑制。MMP13能部分逆转miR-375对OS细胞迁移和侵袭的抑制作用。结论 在OS细胞中,过表达miR-375通过调控MMP13的表达抑制细胞的迁移和侵袭。     

miR-375在AGEs介导糖尿病血管损伤细胞中的生物学功能

目的：探讨miR-375在血管损伤细胞中的表达及生物学功能。方法：利用基因克隆技术构建miR-375表达载体;然后将miR-375表达质粒转染至血管损伤细胞中,同时分别设立Huvec12对照组,血管损伤细胞组,血管损伤抑制组,Huvec12转染miR-375组。24h后收集细胞,在mRNA和蛋白水平检测Mtpn、NFκB、profilin1、sICAM1的表达,经荧光染色观察细胞F-actin的变化,再用流式细胞仪检测细胞凋亡。结果：血管损伤细胞中过表达miR-375后,在mRNA和蛋白水平靶基因Mtpn下降,NFκB的表达活性下降,使糖尿病血管病变的标志profilin1下调;F-actin表达恢复;细胞粘附因子（sICAM1）表达下降,细胞凋亡减少。结论：初步证明miR-375可以抑制AGEs介导的糖尿病血管细胞损伤的发生,可能成为糖尿病血管损伤并发症基因治疗的靶点。     

miR-375 在AGEs介导糖尿病血管损伤细胞中的生物学功能

目的：探讨miR-375 在血管损伤细胞中的表达及生物学功能。方法：利用基因克隆技术构建miR-375表达载体;然后将 miR-375 表达质粒转染至血管损伤细胞中,同时分别设立Huvec12对照组,血管损伤细胞组,血管损伤抑制组,Huvec12 转染 miR-375 组。24h 后收集细胞,在mRNA 和蛋白水平检测Mtpn、NFγB、profilin1、sICAM1 的表达,经荧光染色观察细胞F-actin 的 变化,再用流式细胞仪检测细胞凋亡。结果：血管损伤细胞中过表达miR-375后,在mRNA和蛋白水平靶基因Mtpn 下降,NFγB 的表达活性下降,使糖尿病血管病变的标志profilin1 下调;F-actin 表达恢复;细胞粘附因子（sICAM1）表达下降,细胞凋亡减少。 结论：初步证明miR-375 可以抑制AGEs 介导的糖尿病血管细胞损伤的发生,可能成为糖尿病血管损伤并发症基因治疗的靶点。     

MicroRNA-330 inhibits growth and migration of melanoma A375 cells: In vitro study

Melanoma skin cancer is one of the main causes of male cancer-related deaths worldwide. It has been suggested that miR-330-5p can act as a tumor suppressor in various types of cancers. So, in this study, we replaced miR-330 in melanoma cancer cells by vector-based miR-330 to evaluate the effects of this microRNA on the growth and migration inhibition of melanoma cancer cells, and to determine the molecular mechanisms underlying its action. By using the MTT assay, the IC₅₀ of Geneticin antibiotic was obtained as 460 µg/mL. The results of the qRT-PCR showed the increased expression level of miR-330 and decreased expression levels of MMP-9, CXCR4, Vimentin, melanoma cell adhesion molecule, AKT1, and E2F1 messenger RNA in A375 transfected cells. The cytotoxicity assay results demonstrated the inhibition of cancer cells proliferation. Furthermore, the wound healing test results showed a migration reduction of transfected cells with miR-330 compared with nontransfected ones. In addition, 4′,6-diamidino-2-phenylindoleLB: Luria-Bertani (DAPI) staining revealed the significant nucleus fragmentation in miR-330 replaced cells, which correspond to apoptosis induction in replaced cells. The results showed that increase in miR-330 expression level could significantly inhibit the tumor cell growth and the migration of melanoma cancer cells.     

LUCAT1 as an oncogene in tongue squamous cell carcinoma by targeting miR-375 expression

Emerging studies suggested that lncRNAs play a crucial molecular role in cancer development and progression. LncRNA LUCAT1 has been proved as oncogenic molecular in lung cancer, glioma, osteosarcoma, renal carcinoma and oesophageal squamous cell carcinoma. However, its roles and function mechanisms in tongue squamous cell carcinoma (TSCC) are still unknown. We showed that the expression of LUCAT1 was up-regulated in the TSCC cells and tissues and the higher LUCAT1 expression was associated with the poor overall survival (OS). Knockdown expression of LUCAT1 suppressed TSCC cell proliferation, cycle and migration. In addition, we demonstrated that miR-375 overexpression inhibited the luciferase activity of LUCAT1 wild-type and knockdown LUCAT1 promoted the miR-375 expression in TSCC cell. Furthermore, we indicated that miR-375 expression was down-regulated in the TSCC cell lines and tissues and the lower expression of miR-375 was associated with poor OS. The expression of miR-375 was inversely correlated with LUCAT1 expression in the TSCC tissues. Knockdown LUCAT1 promoted TSCC cell proliferation, cell cycle and migration partly through regulating miR-375 expression. In summary, this study suggested the tumorigenic effect of lncRNA LUCAT1 in TSCC cells by targeting miR-375 expression.     

MicroRNA-34a: a potential therapeutic target in human cancer

MicroRNAs (miRs) are small noncoding RNAs that negatively regulate gene expression by binding to the three untranslated regions of their target mRNAs. Deregulations of miRs were shown to play pivotal roles in tumorigenesis and progression. Recent research efforts have been devoted to translating these basic discoveries into applications that could improve the therapeutic outcome of patients with cancer. MiR-34a is a highly conserved miR throughout many different species. In humans, there are three homologs (hsa-miR34a, hsa-miR-34b and hsa-miR-34c). Early studies have shown that miR-34a acts as a tumor-suppressor gene by targeting many oncogenes related to proliferation, apoptosis and invasion. In this review, we provide a complex overview of miR-34a, including regulating its expression, its known functions in cancer and future challenges as a potential therapeutic target in human cancers.     

miR-9: From function to therapeutic potential in cancer

Malignant neoplasms are regarded as the main cause of death around the world; hence, many research studies were conducted to further perceive molecular mechanisms, treatment, and cancer prognosis. Cancer is known as a major factor for health-related problems in the world. The main challenges associated with these diseases are prompt diagnosis, disease remission classification and treatment status forecast. Therefore, progressing in such areas by developing new and optimized methods with the help of minimally invasive biological markers such as circular microRNAs (miRNAs) can be considered important. miRNA interactions with target genes have specified their role in development, apoptosis, differentiation, and proliferation and also, confirm direct miRNA function in cancer. Different miRNAs expression levels in various types of malignant neoplasms have been observed to be associated with prognosis of various carcinomas. miR-9 seems to implement opposite practices in different tissues or under various cancer incidences by influencing different genes. Aberrant miR-9 levels have been observed in many cancer types. Therefore, we intended to investigate the precise role of miR-9 in patients with malignant neoplasms. To this end, in this study, we attempted to examine different studies to clarify the overall role of miR-9 as a prognostic marker in several human tumors. The presented data in this study can help us to find the novel therapeutic avenues for treatment of human cancers.     

MicroRNA-4728 serves as a suppressor and antagonist of oncogenic MAPK in Burkitt lymphoma

Objective

This study identified the biological role of miR-4728 in Burkitt lymphoma (BL) process.

MicroRNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1

Prostate cancer (PCa) is one of the major health problems of the aging male. The roles of dysregulated microRNAs in PCa remain unclear. In this study, we mined the public published data and found that miR-487a-3p was significantly downregulated in 38 pairs of clinical prostate tumor tissues compared with the normal tissues. We further verified this result by in situ hybridization on tissue chip and quantitative real-time polymerase chain reaction (qRT-PCR) in PCa/normal cells. miR-487a-3p targeting of cyclin D1 (CCND1) was identified using bioinformatics, qRT-PCR and western blot analyses. The cellular proliferation, cell cycle, migration, and invasion were assessed by cell counting kit-8, flow cytometry analysis and transwell assay. We discovered that overexpression of miR-487a-3p suppressed PCa cell growth, migration, invasion by directly targeting CCND1. Knockdown of CCND1 in PCa cells showed similar results. Meanwhile, the expression level of CCND1 was significantly upregulated in the PCa tissues and cell lines, which presented negative correlation with the expression of miR-487a-3p. More important, we demonstrated significantly reduced growth of xenograft tumors of stable miR-487a-3p-overexpressed human PCa cells in nude mice. Taken together, for the first time, our results revealed that miR-487a-3p as a tumor suppressor of PCa could target CCND1. Our finding might reveal miR-487a-3p could be potentially contributed to the pathogenesis and a clinical biomarker or the new potential therapeutic target of PCa.     

MiR-375-3p alleviates the severity of inflammation through targeting YAP1/LEKTI pathway in HaCaT cells

ABSTRACT

Atopic dermatitis (AD) is a relapsing inflammatory skin disease with a complicated pathogenesis. This study aimed to investigate whether miR-375-3p could regulate AD through the Yes-associated protein 1 (YAP1) pathway. In this study, inflammatory response was induced by TNF-α and IFN-γ administration in HaCaT cells. We found that viability and inflammatory factor release, including interleukin-1β (IL-1β) and IL-6, were negatively related to miR-375-3p expression in HaCaT cells. We also found that YAP1 overexpression down-regulated lympho-epithelial Kazal type inhibitor (LEKTI) levels and aggravated viability and inflammation in TNF-α and IFN-γ-treated HaCaT cells. Dual-luciferase reporter assay proved the targeted binding of miR-375-3p and YAP1 3?-UTR. Additionally, the protective effect of miR-375-3p on inflammatory response in TNF-α and IFN-γ-treated HaCaT cells could be impeded by YAP1 overexpression. Collectively, our results suggested that miR-375-3p could modulate HaCaT cell viability and inflammation through the YAP1/LEKTI pathway.